The RANKL-RANK Story

Gerontology

Volumn 61, Issue 6, 2015, Pages 534-542

  Nagy, Vanja ^a   Penninger, Josef M ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Cancer; Estrogen; Immunity; OPG; Osteoclastogenesis; Osteoporosis; RANK; RANKL; Thermoregulation

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SEX HORMONE; TNFSF11 PROTEIN, HUMAN;

BONE TURNOVER; CENTRAL NERVOUS SYSTEM; HORMONAL REGULATION; HUMAN; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BONE REMODELING; FEMALE; IMMUNITY; PHYSIOLOGY;

BONE REMODELING; FEMALE; HUMANS; IMMUNITY; OSTEOPROTEGERIN; RANK LIGAND;

EID: 84946487417     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000371845     Document Type: Review

References (79)

1. Ducy P, Schinke T, Karsenty G: The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
2. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.
3. Rodan GA, Martin TJ: Role of osteoblasts in hormonal control of bone resorption - a hypothesis. Calcif Tissue Int 1981; 33: 349-351.
4. Lacey DL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
5. Nakagawa N, et al: RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253: 395-400.
6. Simonet WS, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
7. Yasuda H, et al: Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-1337.
8. Wong BR, et al: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272: 25190-25194.
9. Anderson DM, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
10. Kong YY, et al: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
11. Kong YY, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
12. Walsh MC, et al: Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24: 33-63.
13. Hanada R, et al: Central control of fever and female body temperature by RANKL/RANK. Nature 2009; 462: 505-509.
14. Shimamura M, et al: OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proc Natl Acad Sci USA 2014; 111: 8191-8196.
15. Hikita A, et al: Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand. J Biol Chem 2006; 281: 36846-36855.
16. Lynch CC, et al: MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7: 485-496.
17. Yavropoulou MP, Yovos JG: Osteoclastogenesis - current knowledge and future perspectives. J Musculoskelet Neuronal Interact 2008; 8: 204-216.
18. Dai XM, et al: Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99: 111-120.
19. Wada T, Nakashima T, Hiroshi N, Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17-25.
20. Nakashima T, et al: Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011; 17: 1231-1234.
21. Armstrong AP, et al: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002; 277: 44347-44356.
22. Lomaga MA, et al: TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13: 1015-1024.
23. Naito A, et al: Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4: 353-362.
24. Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M: Activation of p38 mitogenactivated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000; 486: 23-28.
25. Grigoriadis AE, et al: c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443-448.
26. Iotsova V, et al: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3: 1285-1289.
27. Wong BR, et al: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999; 4: 1041-1049.
28. Whyte MP, et al: Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002; 347: 175-184.
29. Bucay N, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
30. Mizuno A, et al: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615.
31. Guerrini MM, et al: Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008; 83: 64-76.
32. Dougall WC, et al: RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412-2424.
33. Perlot T, Penninger JM: Development and function of murine B cells lacking RANK. J Immunol 2012; 188: 1201-1205.
34. Kawai T, et al: B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006; 169: 987-998.
35. Croucher PI, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534-3540.
36. Akiyama T, et al: The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008; 29: 423-437.
37. Gardner JM, et al: Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008; 321: 843-847.
38. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R: PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 2006; 116: 2869-2879.
39. Evely RS, et al: Structural requirements for the action of parathyroid hormone-related protein (PTHrP) on bone resorption by isolated osteoclasts. J Bone Miner Res 1991; 6: 85-93.
40. Akatsu T, et al: Prostaglandins promote osteoclast- like cell formation by a mechanism involving cyclic adenosine 3′ ,5′ -monophosphate in mouse bone marrow cell cultures. J Bone Miner Res 1989; 4: 29-35.
41. Akatsu T, et al: Role of prostaglandins in interleukin- 1-induced bone resorption in mice in vitro. J Bone Miner Res 1991; 6: 183-189.
42. Takahashi N, et al: Induction of calcitonin receptors by 1 alpha, 25-dihydroxyvitamin D3 in osteoclast-like multinucleated cells formed from mouse bone marrow cells. Endocrinology 1988; 123: 1504-1510.
43. Zallone A: Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann NY Acad Sci 2006; 1068: 173-179.
44. Waldner MJ, Foersch S, Neurath MF: Interleukin- 6 - a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8: 1248-1253.
45. Idowu MO, et al: CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43: 364-373.
46. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-311.
47. Pacifici R: Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043-1051.
48. Bord S, Ireland DC, Beavan SR, Compston JE: The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32: 136-141.
49. Hofbauer LC, et al: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140: 4367-4370.
50. Bellido T, et al: Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995; 95: 2886-2895.
51. Kousteni S, et al: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104: 719-730.
52. Hughes DE, et al: Estrogen promotes apoptosis of murine osteoclasts mediated by TGFbeta. Nat Med 1996; 2: 1132-1136.
53. Kameda T, et al: Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997; 186: 489-495.
54. Cenci S, et al: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106: 1229-1237.
55. Cenci S, et al: Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100: 10405-10410.
56. Fata JE, et al: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103: 41-50.
57. Kovacs CS, Kronenberg HM: Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr Rev 1997; 18: 832-872.
58. Beleut M, et al: Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010; 107: 2989-2994.
59. Mukherjee A, et al: Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression. FASEB J 2010; 24: 4408-4419.
60. Asselin-Labat ML, et al: Control of mammary stem cell function by steroid hormone signalling. Nature 2010; 465: 798-802.
61. Tanos T, et al: Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 2013; 5: 182ra155.
62. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM: Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 2003; 100: 9744-9749.
63. Schramek D, et al: Osteoclast differentiation factor RANKL controls development of progestin- driven mammary cancer. Nature 2010; 468: 98-102.
64. Kartsogiannis V, et al: Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999; 25: 525-534.
65. Blatteis CM, Li S, Li Z, Feleder C, Perlik V: Cytokines, PGE2 and endotoxic fever: a reassessment. Prostaglandins Other Lipid Mediat 2005; 76: 1-18.
66. Jones DH, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440: 692-696.
67. Rossouw JE, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
68. Beral V; Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
69. Cummings SR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
70. Stopeck AT, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
71. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M: Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010; 105: 748-767.
72. Henry DH, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
73. Garcia-Gomez A, Sanchez-Guijo F, Del Canizo MC, San Miguel JF, Garayoa M: Multiple myeloma mesenchymal stromal cells: contribution to myeloma bone disease and therapeutics. World J Stem Cells 2014; 6: 322-343.
74. Thomas DM: RANKL, denosumab, and giant cell tumor of bone. Curr Opin Oncol 2012; 24: 397-403.
75. Schramek D, Sigl V, Penninger JM: RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab 2011; 22: 188-194.
76. Gonzalez-Suarez E, et al: RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468: 103-107.
77. Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC: Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol 2011; 165: 833-840.
78. Loser K, et al: Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-1379.
79. Stolina M, et al: Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 2007; 179: 7497-7505.